Market Cap 1.58B
Revenue (ttm) 277.25M
Net Income (ttm) 27.31M
EPS (ttm) N/A
PE Ratio 72.06
Forward PE 39.70
Profit Margin 9.85%
Debt to Equity Ratio 0.00
Volume 1,688,900
Avg Vol 2,243,562
Day's Range N/A - N/A
Shares Out 124.07M
Stochastic %K 20%
Beta 1.26
Analysts Strong Sell
Price Target $25.25

Latest News on DVAX

Dynavax to Participate in Upcoming Investor Conferences

Feb 25, 2025, 4:10 PM EST - 5 weeks ago

Dynavax to Participate in Upcoming Investor Conferences


Dynavax Advances Board Refreshment Program

Jan 27, 2025, 6:00 AM EST - 2 months ago

Dynavax Advances Board Refreshment Program


Dynavax Announces $200 Million Share Repurchase Program

Nov 7, 2024, 4:01 PM EST - 5 months ago

Dynavax Announces $200 Million Share Repurchase Program


Dynavax Adopts Limited-Duration Stockholder Rights Plan

Oct 29, 2024, 8:30 AM EDT - 5 months ago

Dynavax Adopts Limited-Duration Stockholder Rights Plan


3 'Repeatable' Biotech Trades

Sep 25, 2024, 12:46 PM EDT - 6 months ago

3 'Repeatable' Biotech Trades

FOLD GSK NTLA XBI


Dynavax to Present at Upcoming Investor Conferences

May 28, 2024, 4:18 PM EDT - 11 months ago

Dynavax to Present at Upcoming Investor Conferences


Dynavax Technologies: Still A Believer

Mar 24, 2024, 7:39 AM EDT - 1 year ago

Dynavax Technologies: Still A Believer


Dynavax Technologies: Still A Solid Pick For 2024

Jan 2, 2024, 1:53 PM EST - 1 year ago

Dynavax Technologies: Still A Solid Pick For 2024